The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.
Recurrent or metastatic malignant solid tumors diagnosed by histology or cytology;
ECOG score 0-4 (3-4 points only for patients with tumor burden);
Those who fail or cannot tolerate standard treatment, or those who refuse standard treatment;
At least one measurable lesion that meets the RECIST 1.1 standard;
Patients who have actively undergone or are currently participating in clinical trials for treatment;
Serious or uncontrolled medical diseases (i.e. uncontrolled diabetes, chronic kidney disease, chronic lung disease or uncontrolled active infection, mental diseases/social conditions that limit the compliance with the research requirements) that the researchers think will confuse the research treatment response analysis;
Pregnant or lactating patients, or any patients with fertility, have not taken appropriate pregnancy prevention measures.
9
Treatment groupsSee each treatment group below.